---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-26-000097"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2026-08-07T11:02:16+00:00"
generated_at: "2026-08-07T11:05:14.273001+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q2 2026 revenue up 11% to $8.1M; gross margin record 15%

## Summary
- Q2 2026 total revenue $8.1M, +10.9% YoY; product $5.3M, service $2.8M, recurring $5.0M (+14.3%).
- Gross margin 15.0% vs 3.8% YoY; net loss $12.9M ($0.27/share) vs $11.9M loss ($0.27/share) prior year.
- Placed 4 Growth Direct systems, completed 9 validations; 200th system placed globally.
- Reaffirms FY2026 revenue guidance $37-41M, 30-38 placements, ~20% gross margin; raises validation guidance to at least 27.
- Cash, equivalents and short-term investments ~$20M as of June 30, 2026.

## SEC filing metadata
- accession: 0001380106-26-000097
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2026-08-07T11:02:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000097/0001380106-26-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010626000097/rpid-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-26-000097
- JSON: https://secwatch.observer/filing/0001380106-26-000097.json
- Plain text: https://secwatch.observer/filing/0001380106-26-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.